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Schizophrenia is a psychotic disorder with a prevalence of 1% and three kinds of 
symptoms: 
• Positive: additional to normal experience. Hallucinations, delusions. 
•Negative: lack of normal experience. Depression, social withdrawal. 
•Cognitive: memory and attention alterations, concept disorganization. 
Brain changes are also observed, although they are not specific so they can’t be 
used for diagnosis. The heritability is high (80%), due to some genetic or epigenetic 
changes. There are also environmental risk factors, during both fetal and pre-adult 
life. 
Treatment is focused on blocking dopamine receptors, but antipsychotics are only 
effective against positive symptoms and cause metabolism or motor side effects, so 
investigation in schizophrenia-related brain mechanisms is important for the design 
of new treatments. 
Hypothesis 
Methodology 
Studies and reviews found using the Pubmed database were used for the 
review; the search included keywords such as “Schizophrenia”, “NMDA 
receptors” or “treatment”. Also, Neurochemistry biography was used to 
acquire a basis of knowledge in biochemistry of the brain. 
The aim of this review is to define the new schizophrenia hypothesis and, 
considering the supporting evidence, draw conclusions. This hypothesis states 
that schizophrenia could be caused by a NR dysfunction and its downstream 
effects.  
Conclusions References 
1. Genetic or environmental alteration of NR function causes schizophrenia symptoms. 
2. The cause is the lack of GABAergic regulation of the excitatory system. 
3. NR blocking alters the dopaminergic neurotransmission: association to old hypothesis. 
4. Development alterations have its consequences in late adolescence, after brain 
maduration, so symptoms appear in early adulthood. 
5. Therapies based on this hypothesis have proved to be effective. 
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Therapies based on the hypothesis Causes of NR hypofunction 
GENETIC 
Polymorphisms in some genes have been associated to schizophrenia 
risk.  
• ErbB2: neuregulin-1 receptor, controlling NR’s kinetic 
properties. 
• Dysbindin-1: associated to NR, implication in signalling.  
• G72/G30 complex: regulates the co-agonist D-serine 
degradation. 
Alterations in transcription or translation of NR subunits or 
associated proteins could also be a cause. 
 
NOT GENETIC 
During synaptogenesis (3rd semester of pregnancy) neurons are 
extremely sensitive to glutamate stimulation. 
• Too much stimulation (hypoxia) leads to excitotoxicity. 
• Not enough stimulation (due to NR antagonists) activates 
apoptosis.  
Difficulty: the brain changes causing schizophrenia have already 
taken place, so they can’t be avoided once the symptoms have 
started.  
 
Permanent stimulation of NR using agonists is not a solution: it could 
cause excitotoxicity. Allosteric modulation seems a safer approach. 
Glycine and D-serine modulate GlyB site, on NR1 subunit. Their 
extracellular concentration is controlled by some transporters which 
have been found altered in patients. Daily administration of Glycine 
and D-serine to patients has resulted in improvement. The dose must 
be controlled to avoid side-effects: activation of Glycine R or NR 
internalization. 
 
Acamprosate is used to avoid relapse in alcoholic patients. It 
normalizes glutamate release and NR function without disturbing the 
whole glutamatergic neurotransmission; by acting on GluR5-
depending regulation. The treatment seems effective, even in 
prodromal phase.  
Mechanistic model 
The regulation of Glycine and D-serine extracellular 
levels. 
Exposure to NR antagonists (PCP, ketamine) induce schizophrenia-like symptoms, much more similar than the ones produced by dopaminergic drugs, 
especially in chronic exposures; revealing NR importance. 
 
Glutamate works as an excitatory agent, but also as a main regulator of inhibitory tone. Glutamate-NR interaction activates parvalbumin-positive GABAergic 
interneurons, which inhibit the principal excitatory pathways of the limbic and cortical regions. NR blocking would eliminate this regulation and generate an 
excessive stimulatory stimulus causing morphologic changes in postsynaptic neurons. Afterwards, compensatory systems would diminish the brain activity. 
These morphological changes, taking place during the brain development, could be responsible for adult schizophrenia symptoms and also some 
neurodegeneration. PFC, responsible for personality, decision making, adequacy of social behaviour, etc. is especially affected: parvalbumin levels, metabolic 
activity and the number of GABAergic axon terminals are lower than usual in patients’ PFC.  
Feedback regulation of the excitatory system Evidence 
Administration of NR antagonists. 
i. Early administration in rats increases neuronal death and modifies adult animals’ behaviour: 
hyperlocomotion, stereotyped behaviour, alteration of social and cognitive functions. 
ii. Acute administration in rats increases neurotransmitters’ extracellular concentration and generates 
schizophrenia-like behaviour. Chronic administration is a better model: the effects are persistent, and 
metabolic changes, lesser neuronal density and adaptation mechanisms are also observed. 
iii. Positive and negative symptoms are observed after ketamine administration to healthy humans. In 
patients, also hallucinations and psychosis. Chronic consumers have showed alterations in cognition. 
 
NR importance. 
NR1 knock-out mice die immediately after birth. Mice with hypomorfic NR1 show schizophrenia-like behaviour. NR1 
knock-out in excitatory neurons of PFC led to only cognitive symptoms, while in interneurons it caused all symptoms. 
Point mutations in the glycine binding site or knock-out of NR2 induce some but not all symptoms.  
 
GABAergic system implication. 
In patients: reduction of GABAergic innervations and alteration of GABAA receptors in PFC pyramidal neurons. NR 
antagonist administration also reduces the GABAergic activity. 
Objections 
Why would a deregulation during the development cause an illness that doesn’t start until late 
adolescence? Because the mechanism altered by NR blocking affects processes and neuronal 
connexions that don’t exist until the end of adolescence. The activation of the hyperglutamatergic 
state due to the brain maturation will cause the prodromal phase pre-symptoms that could trigger a 
psychotic episode. Evidence: administration of ketamine would cause psychotic reactions in human 
adults but not in pre-adults. 
NMDA receptor, its union sites and 
antagonists 
Scores of an hypothectical schizophrenic 
patient in different symptoms 
